Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Adding mint flavor to e-cigarette liquids increases the amount of vapour particles produced and is linked, according to a recent study published in Respiratory Research.
Read Full NewsA meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.
Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.
Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.
Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.
Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.
1.
Treating advanced prostate cancer
2.
For treatment, the majority of cancer patients choose complementary therapies.
3.
Study opens up possibility of bespoke prostate cancer treatment
4.
In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.
5.
Telehealth in the pandemic era resulted in fewer therapy interruptions.
1.
CAR T-Cell Therapy: Revolutionizing Hematologic Malignancies
2.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
3.
Understanding Sideroblastic Anemia and its Symptoms
4.
A New Hope: How Procarbazine is Revolutionizing Cancer Treatment
5.
Mitoxantrone–Napabucasin Co-Nanoformulation Activates cGAS-STING in HCC Therapy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
2.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge